Candel

Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Retrieved on: 
Wednesday, August 2, 2023
Candel, Canaccord Genuity, Doctor of Philosophy, MD, Patient, Webcast, Therapy, CADL, Conference, News, Pharmaceutical industry, Broadcasting, Fellow of the Academy of Medical Sciences

NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth Conference, taking place August 7-10, 2023, in Boston.

Key Points: 
  • NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth Conference, taking place August 7-10, 2023, in Boston.
  • A live webcast of the session will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candeltx.com .
  • A replay of the webcast will be archived for up to 90 days following the session date.

Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024

Retrieved on: 
Tuesday, June 13, 2023
ICI, Cohort, Survival, Clinical trial, Fast Track, NSCLC, Lung cancer, Doctor of Philosophy, ASCO, MD, Patient, Data, Aggarwal, Neoplasm, Therapy, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Valaciclovir, Food, Pharmaceutical industry, Candel, Fellow of the Academy of Medical Sciences

“In conjunction with this topline data, we will assess whether the effect on tumor biology previously reported could translate into improved survival, which we believe is what matters to patients and regulators.

Key Points: 
  • “In conjunction with this topline data, we will assess whether the effect on tumor biology previously reported could translate into improved survival, which we believe is what matters to patients and regulators.
  • These data supported the application for Fast Track designation, granted by the U.S. Food and Drug Administration for this program in April 2023 .
  • The Company remains on target to present additional clinical and immunological biomarker activity data in the third quarter of 2023.
  • CAN-2409 is an investigational off-the-shelf viral immunotherapy designed to induce an individualized, systemic immune response against the patient’s specific tumor.

Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors

Retrieved on: 
Thursday, June 8, 2023
Drug development, University, Gene, CMC, Survival, Quality of life, AAV, Pharmacist, Lentivirus, Novartis, MD, Patient, Cell, University of Pavia, Therapy, CADL, Prostate cancer, Orchard, Candel, Doctor of Philosophy, Fellow of the Academy of Medical Sciences

“We are pleased to welcome Nicoletta as a new member of Candel’s Board,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) of Candel.

Key Points: 
  • “We are pleased to welcome Nicoletta as a new member of Candel’s Board,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) of Candel.
  • “Her wealth of strategic and hands-on industry experience in drug development and manufacturing makes her an important addition to our Board as we advance our late-stage oncology programs.
  • She oversaw the integration of the CAR-T teams and AveXis’ AAV technical capabilities into Novartis’ technical research and development.
  • She is also a registered pharmacist and member of the UK Royal and Italian Pharmaceutical societies.

Candel Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

Retrieved on: 
Monday, June 5, 2023
Candel, Webcast, Therapy, CADL, MD, Patient, Conference, News, Doctor of Philosophy, Pharmaceutical industry, Broadcasting, Fellow of the Academy of Medical Sciences

NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will give a corporate presentation at the upcoming Jefferies Healthcare Conference, taking place June 7 – 9, 2023, in New York City.

Key Points: 
  • NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will give a corporate presentation at the upcoming Jefferies Healthcare Conference, taking place June 7 – 9, 2023, in New York City.
  • A live webcast of the session will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candel.com .
  • A replay of the webcast will be archived for up to 90 days following the session date.

Candel Therapeutics Announces New Data from Ongoing Phase 1 Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

Retrieved on: 
Friday, May 19, 2023
HSV, Survival rate, Injection, Arm, Histology, Gene, Neoplasm, Survival, Clinical trial, Cyclophosphamide, Nestin, SOC, Doctor of Philosophy, HIV disease progression rates, MD, Patient, Standard of care, Cell, MOS, Therapy, CADL, Society, Safety, Pharmaceutical industry, Vaccine, Candel, Fellow of the Academy of Medical Sciences

The data were presented today in an Oral Presentation Session at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).

Key Points: 
  • The data were presented today in an Oral Presentation Session at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
  • “We are encouraged by the increased survival of treated patients in two independent cohorts observed to date.
  • mOS in arm B is ongoing at 12.0 months and supports the encouraging clinical activity of CAN-3110 observed in in arm A.
  • Additional extensive biomarker studies including histology, transcriptomics, and single cell sequencing are ongoing.

Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, May 11, 2023
Pancreatic cancer, Injection, University, Gene, Quarter, Survival, Clinical trial, Quality of life, Lung cancer, University of Pennsylvania, NSCLC, SOC, Perelman School of Medicine at the University of Pennsylvania, Doctor of Philosophy, Associate, ASCO, Development, American Society of Clinical Oncology, Patient, Standard of care, Administration, HGG, Annual general meeting, Cell, American Society of Gene and Cell Therapy, Cancer, PD-1, Research, FDA, Therapy, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, MPH, Valaciclovir, Society, MOS, Food, Prostate cancer, Pharmaceutical industry, Q3, Candel, Fellow of the Academy of Medical Sciences, MD

NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

Key Points: 
  • NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.
  • Financial Results for the Quarter Ended March 31, 2023
    Research and Development Service Revenue, related party: Research and development service revenue, related party, was $0 for the first quarter of 2023 compared to $31,000 for the first quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $5.5 million for the first quarter of 2023 compared to $5.4 million for the first quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $4.2 million for the first quarter of 2023 compared to $3.6 million for the first quarter of 2022.

Candel Therapeutics Announces Upcoming Presentations at ASGCT and ASCO

Retrieved on: 
Tuesday, May 2, 2023
University, Gene, Safety, Candel, Clinical trial, Lung cancer, University of Pennsylvania, NSCLC, American Society of Gene and Cell Therapy, Associate, ASCO, American Society of Clinical Oncology, Patient, Perelman School of Medicine at the University of Pennsylvania, Annual general meeting, Public, Survival, Cell, MPH, Therapy, CADL, Society, Valaciclovir, Pharmaceutical industry, MD

NEEDHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced an abstract detailing new data from its phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma was accepted as an oral presentation in the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA and virtually, May 16-20, 2023.

Key Points: 
  • NEEDHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced an abstract detailing new data from its phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma was accepted as an oral presentation in the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los Angeles, CA and virtually, May 16-20, 2023.
  • Additionally, the Company will present a trials-in-progress poster from its phase 2 clinical trial of CAN-2409 plus valacyclovir and anti-PD1 antibodies in patients with stage III/IV non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology (ASCO) 27th Annual Meeting in Chicago, IL and virtually, June 2-6, 2023.
  • Oral Presentation Title: Safety and Survival Outcomes in Recurrent High-Grade Glioma Patients Treated with CAN-3110, a First-in-Class ICP34.5 Expressing Oncolytic HSV1
    Presenter: Charu Aggarwal, MD, MPH, Associate Professor for Lung Cancer Excellence, Perelman School of Medicine, University of Pennsylvania

Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Non-Small Cell Lung Cancer

Retrieved on: 
Monday, April 17, 2023
Survival, Clinical trial, Lung cancer, NSCLC, Doctor of Philosophy, HIV disease progression rates, MD, Patient, Neoplasm, PD-1, FDA, Pembrolizumab, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Valaciclovir, Food, Pharmaceutical industry, Candel, Fellow of the Academy of Medical Sciences

Fast track designation is a process designed to facilitate the development and expedite the review of medicines to treat serious conditions and fulfill an unmet medical need.

Key Points: 
  • Fast track designation is a process designed to facilitate the development and expedite the review of medicines to treat serious conditions and fulfill an unmet medical need.
  • An investigational medicine that receives fast track designation may be eligible for more frequent interactions with the FDA to discuss the candidate’s development plan and, if relevant criteria are met, eligibility for accelerated approval and priority review.
  • “We are pleased with the FDA's decision to grant fast track designation for CAN-2409, which reinforces our belief that our investigational medicine has meaningful potential to treat those living with late-stage lung cancer,” said Paul Peter Tak, MD, PhD, FMedSci, President and CEO of Candel.
  • “Despite progress made in recent years, there remains a significant unmet need for patients with lung cancer who have an inadequate response to standard of care immune checkpoint inhibitors.

Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 30, 2023
HSV, Pancreatic cancer, Insurance, Herpes simplex virus, University, Partnership, ICI, Survival, Clinical trial, Silicon Valley Bank, Immunotherapy, Nestin, Toxicity, Brain, NSCLC, Lung cancer, Doctor of Philosophy, TWELVE, Rated R, MS, University of Pennsylvania, Silicon, Development, HIV disease progression rates, Patient, Standard of care, Content discovery platform, Administration, HGG, Biology, PD-1, Research, Therapy, CADL, Tumor microenvironment, PD-L1, Valaciclovir, Nivolumab, Prostate cancer, Enlightenment, Pharmaceutical industry, Vaccine, Medical imaging, Cryptocurrency, Society, Candel, SOC, Cancer, Fellow of the Academy of Medical Sciences, MD

In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.

Key Points: 
  • In addition, a single injection of CAN-3110 in patients with recurrent high-grade glioma resulted in a median overall survival of 11.6 months.
  • Importantly, CAN-2409 demonstrated a favorable change in the trajectory of tumor growth in all patients for whom pre-enrollment scans were available.
  • The Company is encouraged by the results and plans to present additional data in Q3 2023.
  • Research and Development Expenses: Research and development expenses were $5.0 million for the fourth quarter of 2022 compared to $3.9 million for the fourth quarter of 2021, and $20.8 million for the full-year 2022 compared to $15.2 million for the full-year 2021.

Citryll Announces the Appointment of Paul Peter Tak as Chair of the Board of Directors

Retrieved on: 
Thursday, March 30, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, GSK, GSK plc, University, Netherlands Society for Statistics and Operations Research, Therapy, Senior, Arthritis, Medicine, European Alliance of Associations for Rheumatology, Infection, Cancer, University of California, San Diego, Fellow of the Academy of Medical Sciences, ViiV Healthcare, Doctor of Philosophy, Pain, Professor, Patient, Hidradenitis suppurativa, Medal, Immune-mediated inflammatory diseases, EULAR, Victoria Medal of Honour, Leiden University Medical Center, European Alliance, Rheumatoid arthritis, Pharmaceutical industry, Candel, Rheumatology, Citryl-CoA lyase

Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat autoimmune and autoinflammatory diseases, today announced that Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.

Key Points: 
  • Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat autoimmune and autoinflammatory diseases, today announced that Dr. Paul Peter Tak, Citryll Board member since 2021, has been appointed Chair of the Board of Directors.
  • At GlaxoSmithKline (GSK) Paul Peter served as Senior Vice President, Chief Immunology Officer and Global Development Leader.
  • He was the Chair of GSK’s Scientific Review Board, the governing body accountable for the scientific assessment of its R&D portfolio.
  • “We are delighted to welcome Paul Peter as Chair of the Board of Directors.